Hereditary Breast Cancer ASCO-ASTRO-SSO Guideline

Consensus

Hereditary Breast Cancer ASCO-ASTRO-SSO Guideline

ForBreast cancer with germline BRCA1/2, PALB2, CHEK2, ATM or TP53 mutation

TL;DRRT not withheld for mutation status (strong rec), except germline TP53, where intact-breast RT is contraindicated; BCT stays open to BRCA1/2 carriers.

Why it mattersRadiation oncology

The panel graded the RT recommendations unevenly. Not withholding RT for BRCA1/2 or moderate-penetrance status is a strong rec on intermediate evidence, but the ATM rec rests on low evidence, so a toxicity concern is a counseling topic, not a reason to omit RT. TP53 is the only exclusion, and even there PMRT stays available with significant LRR risk.

Monday clinic

In a newly diagnosed BRCA1/2 or ATM carrier otherwise eligible for breast conservation, this supports keeping BCT plus indicated RT on the table; it does not extend to germline TP53 carriers, for whom intact-breast RT is contraindicated.

9 details 2 trials watching

Design

Joint ASCO/ASTRO/SSO expert panel; systematic review plus formal consensus with two voting rounds. 58 articles for local therapy, 6 RCTs (published 2017 to 2018) for systemic therapy.

Population & inclusion

Women with breast cancer carrying germline BRCA1/2, PALB2, CHEK2 or ATM mutations, early or advanced stage; TP53 addressed for RT. Panel states management should be largely the same for men.

Radiotherapy

RT should not be withheld because of mutation status after BCT or when PMRT is considered (Rec 6.1, strong). ATM carriers: offer RT when indicated (6.2). Germline TP53: intact-breast RT contraindicated, PMRT only with significant LRR risk (6.3).

Regimen

Metastatic BRCA carriers: platinum preferred over taxane if platinum-naive; olaparib or talazoparib as an alternative to chemo in metastatic HER2-negative disease, 1L to 3L. No routine platinum added to anthracycline/taxane (neo)adjuvant chemo; no PARPi in nonmetastatic disease.

Results

Round 1 agreement ranged 72% to 98%, mean 90%. One of 17 recs (moderate-gene CRRM) failed the 75% threshold and passed at 90% after revision.

Rec	Population	Recommendation	Evidence	Strength
6.1	BRCA1/2 or moderate-penetrance gene	RT not withheld for mutation status after BCT or when PMRT considered	Intermediate	Strong
6.2	ATM carriers	Offer RT when clinically indicated; discuss with those considering BCT	Low	Moderate
6.3	Germline TP53 carriers	Intact-breast RT contraindicated; mastectomy; PMRT only with significant LRR risk	Low	Moderate

Decision	BRCA1/2	Moderate-penetrance
BCT for index cancer	Not precluded; discuss CBC and ipsilateral new primary risk	Offer when BCT appropriate
CRRM	Discuss; lowers CBC, no proven survival gain	Not based predominantly on mutation status
Nipple-sparing mastectomy	Reasonable in selected pts	Reasonable in selected pts
Surveillance without bilateral mastectomy	Annual mammogram + MRI	Annual mammogram + MRI
Metastatic chemo	Platinum preferred over taxane if platinum-naive	No platinum efficacy data
PARPi, metastatic HER2-negative	Olaparib or talazoparib, 1L to 3L	No supporting data
(Neo)adjuvant	No routine platinum add-on; PARPi not recommended	No data

vs leading data

Systemic recs lean on TNT for platinum and OlympiAD/EMBRACA for PARPi. TNT included only 11 BRCA carriers with ER-positive disease, so the platinum preference extrapolates thinly to ER-positive carriers.

Applies to

germline BRCA1/2 and moderate-penetrance (PALB2, CHEK2, ATM) carriers with breast cancer weighing BCT, RT, CRRM or systemic options

Does not represent somatic-only BRCA tumors, where PARPi efficacy data are absent.

Limitations

Rec 4.1 wording ('offered') diverges from Table 2 and the abstract ('discussed') for BRCA1/2 CRRM. ATM pathogenicity is unsettled for most missense variants, which confounds the RT toxicity literature the panel reviewed.

Discussion

The RT message is permissive: genotype is not a reason to omit indicated RT outside TP53. The adjuvant PARPi stance (Rec 10) predates the OlympiA readout and is the rec most likely to have aged.

Rationale

Formal-consensus guideline; RT recs rest on intermediate to low evidence from nonrandomised series. Agreement figures measure panel opinion, not outcomes.

Open questions

Does heterozygous ATM status raise RT toxicity or contralateral risk?
Do PARP inhibitors work in PALB2, CHEK2 or ATM carriers?

not yet PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations Carriers Phase 2

n=12 · primary completion 2024-09 · single-arm niraparib in germline PALB2 MBC, BRCA wt

active Olaparib In Metastatic Breast Cancer Phase 2

n=114 · primary completion 2025-07 · olaparib in MBC with CHEK2, ATM or PALB2 mutations
Platinum vs anthracycline neoadjuvant chemo in BRCA carriers

📚 Sources · 📄 1 paper

📄 PAPER Tung, Nadine M.; Boughey, Judy C.; Pierce, Lori J. et al. · Journal of Clinical Oncology (2020-06)

Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline

doi

Abstract

PURPOSE To develop recommendations for management of patients with breast cancer (BC) with germline mutations in BC susceptibility genes. METHODS The American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology convened an Expert Panel to develop recommendations based on a systematic review of the literature and a formal consensus process. RESULTS Fifty-eight articles met eligibility criteria and formed the evidentiary basis for the local therapy recommendations; six randomized controlled trials of systemic therapy met eligibility criteria. RECOMMENDATIONS Patients with newly diagnosed BC and BRCA1/ 2 mutations may be considered for breast-conserving therapy (BCT), with local control of the index cancer similar to that of noncarriers. The significant risk of a contralateral BC (CBC), especially in young women, and the higher risk of new cancers in the ipsilateral breast warrant discussion of bilateral mastectomy. Patients with mutations in moderate-risk genes should be offered BCT. For women with mutations in BRCA1/ 2 or moderate-penetrance genes who are eligible for mastectomy, nipple-sparing mastectomy is a reasonable approach. There is no evidence of increased toxicity or CBC events from radiation exposure in BRCA1/ 2 carriers. Radiation therapy should not be withheld in ATM carriers. For patients with germline TP53 mutations, mastectomy is advised; radiation therapy is contraindicated except in those with significant risk of locoregional recurrence. Platinum agents are recommended versus taxanes to treat advanced BC in BRCA carriers. In the adjuvant/neoadjuvant setting, data do not support the routine addition of platinum to anthracycline- and taxane-based chemotherapy. Poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and talazoparib) are preferable to nonplatinum single-agent chemotherapy for treatment of advanced BC in BRCA1/ 2 carriers. Data are insufficient to recommend PARP inhibitor use in the early setting or in moderate-penetrance carriers. Additional information available at www.asco.org/breast-cancer-guidelines .

Consensus / guideline Consensus

The longer read

For a radiation oncologist, this guideline does one thing above all else. It takes germline status off the list of reasons to withhold indicated RT, with one exclusion. Rec 6.1 is graded strong on intermediate evidence, which is an unusual pairing. The panel is more confident in its conclusion than in the data behind it. The logic is asymmetric. The reviewed literature showed no signal of excess toxicity or contralateral events from RT in BRCA1/2 carriers, while omitting indicated RT has a known cost. The burden of proof falls on whoever wants to omit RT. That framing is defensible, but readers should see it for what it is: absence of evidence of harm, drawn from 28 mostly observational studies, not a randomised demonstration of safety.

The ATM recommendation is where the evidence is thinnest, and the panel says so. Biallelic ATM loss confers radiosensitivity, and case reports of toxicity in heterozygous carriers exist. One reviewed study found more contralateral cancers in carriers of rare predicted-deleterious ATM variants who received RT. The panel discounted that study for two reasons: other studies were inconsistent with it, and it is unclear which included variants are pathogenic. That second point matters beyond this guideline. Most ATM variants are missense, so any series that pools them mixes true mutations with benign variants and dilutes or distorts a real effect in both directions. Until variant-level data exist, the honest position is the one the panel took: offer RT, and discuss the uncertainty with ATM carriers who are considering BCT.

TP53 is handled differently, and correctly so. Intact-breast RT is contraindicated and mastectomy is recommended. The panel still leaves room for PMRT when locoregional risk is significant, which avoids turning a sound concern about radiation-induced malignancy in Li-Fraumeni into an absolute ban that could undertreat node-positive disease.

On local therapy more broadly, the guideline separates control of the index cancer from future-cancer risk. Local control after BCT in BRCA1/2 carriers is described as similar to that in noncarriers, so the BCT versus mastectomy discussion is really about the risk of contralateral and new ipsilateral primaries, with age as the strongest predictor. That reframing keeps the RT plan from being contaminated by a surgical decision driven by prevention. One internal inconsistency deserves attention. The abstract and Table 2 say BRCA1/2 CRRM should be discussed, while Rec 4.1 says it should be offered. These carry different implications for consent.

The systemic recommendations have aged faster than the local ones. The adjuvant PARP inhibitor stance was written while OlympiA was pending, and the platinum preference generalises from a TNT subset with few ER-positive carriers. The RT recommendations depend less on any single pending trial, which is why they are likely to hold up better.